Federal Cannabis Reform Continues to Evolve as Congress Eyes Impairment Standards

Federal marijuana policy continues to shift in 2026, with lawmakers and federal agencies taking new steps that could significantly impact the future of medical marijuana, workplace compliance, and impaired driving standards. While broader federal legalization remains unresolved, recent developments show that Washington is moving toward a more structured and science-based approach to cannabis regulation. 

Earlier this year, federal officials advanced a limited rescheduling effort that primarily affects FDA-approved cannabis products and state-regulated medical marijuana programs. The move represents a major policy change because it formally acknowledges medical cannabis use at the federal level, even though recreational marijuana remains federally illegal. The rescheduling effort is expected to improve medical cannabis research opportunities and potentially reduce some tax burdens on qualifying medical marijuana businesses. 

However, many important legal and employment-related restrictions remain unchanged. Federal agencies, including the Department of Transportation (DOT), have clarified that marijuana use is still prohibited for safety-sensitive workers such as truck drivers, airline pilots, and railroad employees, regardless of state medical marijuana laws. Positive marijuana drug tests may still result in disciplinary action under federal transportation regulations. 

At the same time, Congress is now addressing another major issue surrounding cannabis legalization: impairment testing.

A bipartisan transportation bill recently approved by a congressional committee would require federal agencies to study marijuana and polysubstance impairment and develop “evidence-based impairment standards” for drivers. The proposal is part of the larger “Building Unrivaled Infrastructure and Long-term Development (BUILD) for America’s 250th Act,” introduced by House Transportation and Infrastructure Committee leaders Rep. Sam Graves (R-MO) and Rep. Rick Larsen (D-WA). 

Currently, there is no universally accepted federal standard for determining marijuana impairment behind the wheel. Unlike alcohol, where blood alcohol concentration (BAC) thresholds are widely recognized, cannabis impairment remains difficult to measure accurately. Existing marijuana tests often detect THC metabolites long after impairment has ended, creating challenges for employers, law enforcement, and regulators. 

The proposed legislation would direct the Department of Transportation and other federal agencies to:

• study how marijuana and polysubstance use affects driving,

• analyze methods for detecting impairment,

• establish evidence-based impairment standards, and

• create a national crash data collection system involving toxicology and accident reporting. 

  
  

The bill also proposes more than $110 million in federal funding from 2027 through 2031 to support research, toxicology labs, state pilot programs, and data collection systems. 

For employers and safety-sensitive industries, these developments could eventually lead to more reliable and consistent workplace impairment policies. Many organizations have struggled to balance evolving state marijuana laws with federal compliance requirements and employee safety concerns. A federally recognized impairment standard could help reduce uncertainty while providing a more science-driven framework for evaluating impairment. 

Although federal cannabis reform is still evolving, recent actions suggest policymakers are increasingly focused on practical regulation rather than outright prohibition. Medical marijuana programs are receiving greater federal recognition, research barriers are slowly being reduced, and lawmakers are beginning to address long-standing concerns surrounding cannabis impairment and public safety. 

Working Partners® will continue to monitor this situation and keep you updated.